Stephen Zarrilli Sells 25,000 Shares of Globus Medical (NYSE:GMED) Stock

Globus Medical, Inc. (NYSE:GMED) Director Stephen Zarrilli sold 25,000 shares of the stock in a transaction dated Tuesday, August 18th. The stock was sold at an average price of $87.04, for a total transaction of $2,176,000.00. Following the transaction, the director directly owned 25,000 shares of the company’s stock, valued at $2,176,000. This represents a 50.00% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website.

Globus Medical Trading Down 3.0%

Shares of GMED opened at $85.67 on Friday. Globus Medical, Inc. has a twelve month low of $54.15 and a twelve month high of $101.40. The stock’s 50 day moving average is $80.45 and its two-hundred day moving average is $84.77. The firm has a market capitalization of $11.50 billion, a PE ratio of 21.91, a P/E/G ratio of 1.42 and a beta of 0.95.

Globus Medical (NYSE:GMED) last issued its earnings results on Thursday, August 6th. The medical device company reported $1.34 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.10 by $0.24. The business had revenue of $789.61 million during the quarter, compared to the consensus estimate of $782.88 million. Globus Medical had a return on equity of 14.57% and a net margin of 17.02%.The company’s revenue for the quarter was up 5.9% on a year-over-year basis. During the same period in the prior year, the business posted $0.86 EPS. Globus Medical has set its FY 2026 guidance at 4.950-5.050 EPS. On average, sell-side analysts predict that Globus Medical, Inc. will post 4.99 EPS for the current year.

Wall Street Analysts Forecast Growth

GMED has been the topic of several research analyst reports. Wall Street Zen lowered shares of Globus Medical from a “strong-buy” rating to a “buy” rating in a research report on Saturday, May 9th. Weiss Ratings reiterated a “hold (c+)” rating on shares of Globus Medical in a report on Monday, July 13th. Piper Sandler reduced their price objective on shares of Globus Medical from $115.00 to $100.00 and set an “overweight” rating for the company in a research note on Monday, June 15th. Stifel Nicolaus decreased their price objective on shares of Globus Medical from $95.00 to $80.00 and set a “hold” rating on the stock in a report on Wednesday, July 8th. Finally, Needham & Company LLC upped their target price on shares of Globus Medical from $114.00 to $117.00 and gave the stock a “buy” rating in a research report on Friday, May 8th. Three research analysts have rated the stock with a Strong Buy rating, nine have issued a Buy rating and five have given a Hold rating to the stock. According to MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and an average price target of $101.77.

Institutional Trading of Globus Medical

Institutional investors have recently bought and sold shares of the company. Proficio Capital Partners LLC purchased a new position in shares of Globus Medical in the second quarter valued at $218,000. Wellington Management Group LLP raised its stake in shares of Globus Medical by 16.1% during the 2nd quarter. Wellington Management Group LLP now owns 35,066 shares of the medical device company’s stock worth $2,771,000 after buying an additional 4,851 shares during the last quarter. Public Employees Retirement System of Ohio purchased a new stake in shares of Globus Medical in the 2nd quarter worth about $7,941,000. American Capital Management Inc. purchased a new stake in shares of Globus Medical in the 2nd quarter worth about $51,599,000. Finally, Paradigm Capital Management Inc. NY acquired a new stake in Globus Medical in the 2nd quarter valued at about $70,042,000. 95.16% of the stock is currently owned by hedge funds and other institutional investors.

Globus Medical Company Profile

Globus Medical, Inc (NYSE:GMED) is a leading medical device company specializing in musculoskeletal solutions for spine and orthopaedic applications. Founded in 2003 by David C. Paul and headquartered in Audubon, Pennsylvania, the company develops, manufactures and markets implantable devices and surgical instruments designed to treat spinal disorders and promote bone healing. Its product portfolio encompasses solutions for minimally invasive and open surgical procedures, including interbody fusion devices, pedicle screw systems, and biologics used to enhance fusion outcomes.

In addition to its core spine business, Globus Medical has expanded into robotics and navigation systems to support precision and efficiency in the operating room.